Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Glycomimetics Inc
(NQ:
GLYC
)
0.1850
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glycomimetics Inc
< Previous
1
2
3
Next >
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
July 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
June 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
May 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
May 06, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
March 27, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
March 13, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
February 26, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 12, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
January 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
December 10, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
November 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
October 20, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
September 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
August 02, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
June 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
June 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
May 31, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
May 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
March 29, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
March 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
March 01, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee
February 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.